Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This main purpose of this clinical study is to learn about the safety and activity of
margetuximab and pembrolizumab combination treatment in patients with HER2+ gastric and
gastroesophageal junction cancer.